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ABSTRACT 
 In the present work, some new imidazole derivatives (3i-xii) were synthesized as per design 
synthetic protocol scheme. The structures of newly prepared compounds were confirmed by 
modern analytical technique (IR, 
1
H-NMR, Mass spectral data) and elemental analysis, results 
found in full agreement with their assigned structures. All the synthetic compounds were 
screened for their antimicrobial activity against bacterial strains viz. Escherichia coli (E. coli, 
MTCC 2961), Staphylococcus aureus (S. aureus, MTCC 3160), Bacillus subtilis (B. subtilis, 
MTCC 121), Klebsiella pneumoniae (K. pneumoniae, MTCC 3040) and Micrococcus luteus 
(M. luteus, MTCC 7527)) and fungal strains viz. Candida albicans (C. albicans, MTCC 227), 
Aspergillus niger (A. niger, MTCC 277) and Aspergillus flavus (A. flavus, MTCC 418) ; 
results showed good to remarkable activity. The MIC (minimum inhibitory concentration) 
values were determined by comparison to ciprofloxacin (anti-bacterial) and fluconazole (anti-
fungal) as standard drug. Among them, compound 3iv and 3x exhibited notable antimicrobial 
activity. These compounds may be used as new template for the searching of potential 
antimicrobial agents. 
 
Introduction
The main aim of medicinal chemist in the recent times has 
been to develop drugs with enhanced their efficacy and 
duration of action and by decreasing their toxicities and side 
effects as well as creating new drugs by molecular 
modification [1-2]. The pharmaceutical industry and 
specifically, a medicinal chemist have continued commitment 
towards this drug development. The organic medicinal 
substances can be of natural or synthetic origin. The synthetic 
drugs are prepared by modifications of the structures of 
natural drugs, or by pure synthesis [3-4]. Over the years, 
innovations in new drug therapy has become, more complex, 
time consuming, costly, and the practicing medicinal chemists 
have been bombarded with surplus new methods and 
technologies to make the job of drug discovery more efficient 
[5]. The heterocyclic ring comprises the core of the active 
moiety or pharmacophore. By far the most numerous and most 
important heterocyclic systems are those of five and six 
membered ring. For example, pyrazoles, imidazoles, triazoles, 
thiadiazoles, triazolo-thiadiazoles, oxadiazoles, isoxazoles, 
isothiazole, oxazoles, thiazoles etc. Imidazoles are a class of 
five membered heterocyclic compounds having two nitrogen 
and three carbon atoms. Imidazole is an important group of 
compounds reported to have different biological activities and 
the present study was undertaken in order to synthesize some 
new derivatives of imidazole and related fused heterocyclic 
compounds and screen for their antimicrobial activity [6-
12].The infections of systemic bacterial and fungal has been 
increasing serious and growing threatens to human health over 
the past few decades. Currently present potent antimicrobial 
agents for the management of infections may develop 
microbial resistance to existing drugs a major concern in 
antimicrobial therapy and many compounds have been 
synthesized with this aim but their clinical use has been 
limited by their relatively high risk of toxicity, microbial 
resistance and pharmacokinetic deficiencies. Among the 
various classes of heterocyclic compounds, imidazole is an 
important component of pharmacologically active compounds 
and a part of various available marketed drugs like 
Azathioprine (Leukemia), Metronidazole (Protozoal and 
antimicrobial activity, trichomoniasis, amoebiasis and 
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giardiasis), Dacarbazine (Hodgkin’s disease), Tinidazole 
(Metronidazole), Ornidazole (Antiprotozoal and antibacterial 
activity), Satranidazole (C 10213 Go), (Trichomoniasis and 
amoebiasis), Cimetidtne (Duodenal and gastric ulcers), 
Carbimazole (Thyroid disorders), Tolazoline (Vasodilator 
action), Naphazoline (Vasoconstrictor), Tetrahydrozoline 
(Vasoconstrictor) [12-15]. Recent studies have been revealed 
that the substituted imidazole derivatives attracted attention 
due to their broad spectrum of pharmacological activities such 
as anti-inflammatory, analgesic, antimicrobial, antiviral, 
antifungal, antibacterial, anti-tubercular, anti-cancer, anti-
hypertensive, anti-obesity and anti-convulsant [15-16]. In the 
present studies it has been thought to synthesize newer 
imidazole derivatives and the structures of the synthesized 
compounds confirmed on the basis of their elemental analysis 
and modern analytical techniques such as IR, 1H-NMR and 
Mass spectral data results. 
 
Experimental Protocol 
 
General materials and instrumentations 
All the chemicals and solvent procured from E. Merck and S. 
D. Fine chemicals (India). Melting points were determined by 
open tube capillary method and are uncorrected. Thin layer 
chromatography (TLC) plates prepared by silica gel G were 
used to monitor the reaction as well as to confirm the purity of 
the compound by using solvent systems as  toluene: ethyl 
acetate: formic acid (5:4:1), benzene: acetone (9:1) were used 
to run the TLC. The spots were visualized under iodine 
vapours/UV light. IR spectra were obtained on a Perkin-Elmer 
1720 FT-IR spectrometer using KBr Pellets. 1H-NMR spectra 
were recorded on DPX-300 and BRUKER-400 Ultra 
ShieldTM NMR spectrometer, using TMS as internal standard 
in CDCl3/DMSO-d6. Microanalysis of the compounds was 
done on Perkin-Elmer model 240 analyzer and the values were 
found within ±0.4% of the theoretical values. Mass  
spectrometry was recorded on LC-MS/MS (WATERS, mass 
lyns version 4.1) spectrometer. 
Synthesis 
The compounds of the synthetic protocol scheme were 
obtained in the following steps 
Synthesis of 1-(Biphenyl-4-yl) ethanone (1): The starting 
material biphenyl ethanone (1) was prepared by heating 
biphenyl with anhydrous AlCl3 in presence of CS2 and acetic 
anhydride. The usual work up of the reaction mixture followed 
by recrystallized from ethanol gave pure compound. The 
purity of the compound was verified with the help of TLC (B: 
A, 9 : 1). Percentage yield was found 85% and noted Mp.158-
160°C. IR spectra are very informative and provided evidence 
for the formation of the expected structures.  
Synthesis of 2-(Biphenyl-4-yl)-2-oxoacetaldehyde (2): 
Compound 2-(Biphenyl-4-yl)-2-oxoacetaldehyde (2) was 
synthesized from biphenyl ethanone (1) in presence of 
selenium dioxide, usual work up of the reaction mixture gave 
a yellow liquid which was found pure on TLC examination 
(TEF 5: 4: 1). The structure of compound was confirmed on 
the basis of spectral studies.  
General procedure for synthesis of 4-(Biphenyl-4-yl)-2-
(substituted phenyl)-1H-imidazole (3i-xii): Biphenyl-2-
oxoacetaldehyde (2) was refluxed with different aromatic 
aldehyde in presence of ammonium acetate and glacial acetic 
acid. The usual work up of the reaction mixture followed by 
recrystallized from acetone to get the desired products (3i-xii). 
The structures of compounds were confirmed on the basis of 
their IR and 1H-NMR spectral studies. The compound was 
found pure on TLC examination (BA 9: 1) and (TEF 5: 4: 1) 
and its spectral data was found satisfactory for the proposed 
structures.  
Synthesis of 4-(biphenyl-4-yl)-2-phenyl-1H-imidazole (3i): 
Yield: 70%, Mp: 134-137ºC, Rf = 0.53. IR (KBr, cm-1): 
3450(C-H, N-H), 3041(C-H, Ar-H), 2871(C-H, CH2), 
1595(C=N), 1564 (C=C).  1H-NMR (DMSO-d6, δ, ppm): 
10.93 (H, s, N-H), 6.53-8.79 (H, m, Ar-H), 7.92 (1H, s, CH, 
imidazole). ESI-MS (m/z): 296 (M+). Anal.calcd. for 
C21H16N2: C, 65.11; H, 5.44; N, 9.45. Found: C, 75.11; H, 
4.44; N, 9.51. 
Synthesis of 4-(4-(biphenyl-4-yl)-1H-imidazol-2-yl)phenol 
(3ii): Yield: 75%, Mp: 151-154°C, Rf = 0.54. IR (KBr, cm-1): 
3397(C-H, N-H), 3213(OH), 3035(C-H, Ar-H), 2931(C-H, 
CH2), 1675(C=N), 1556 (C=C). 1H-NMR (DMSO-d6, δ, 
ppm): 10.51 (H, s, N-H), 8.01-6.79 (H, m, Ar-H), 9.01 (1H, s, 
CH, imidazole), 9.46 (H, s, OH). ESI-MS (m/z): 312 (M+). 
Anal.calcd. for C21H16N2O: C, 80.75; H, 5.16; N, 8.97. 
Found: C, 80.79; H, 4.11; N, 8.95. 
Synthesis of 4-(biphenyl-4-yl)-2-(3-chlorophenyl)-1H-
imidazole (3iv): Yield: 77%, Mp: 148-151°C, Rf = 0.47. IR 
(KBr, cm-1): 3405(C-H, N-H), 3021(C-H, Ar-H), 2947(C-H, 
CH2), 1623(C=N), 1564 (C=C), 733(C-Cl). 1H-NMR 
(DMSO-d6, δ, ppm): 9.97 (H, s, N-H), 7.85-6.59 (H, m, Ar-
H), 8.93 (1H, s, CH, imidazole). ESI-MS (m/z): 330 (M+). 
Anal.calcd. for C21H15ClN2: C, 76.24; H, 4.57; N, 8.47. 
Found: C, 76.27; H, 4.54; N, 8.37. 
Synthesis of 3-(4-(biphenyl-4-yl)-1H-imidazol-2-yl)phenol 
(3v): Yield: 64%, Mp: 132-133°C, Rf = 0.53. IR (KBr, cm-1): 
3451(C-H, N-H), 3267(OH), 3058(C-H, Ar-H), 2879(C-H, 
CH2), 1578(C=N), 1551 (C=C). 1H-NMR (DMSO-d6, δ, 
ppm): 10.23 (H, s, N-H), 7.95-6.73 (H, m, Ar-H), 8.31 (1H, s, 
CH, imidazole), 9.37 (H, s, OH). ESI-MS (m/z): 312 (M+). 
Anal.calcd. for C21H16N2O: C, 64.75; H, 5.16; N, 8.97. 
Found: C, 60.79; H, 5.21; N, 8.95. 
Synthesis of 4-(biphenyl-4-yl)-2-(4-chlorophenyl)-1H-
imidazole (3vi):  Yield: 72%, Mp: 185-187°C, Rf = 0.47. IR 
(KBr, cm-1): 3379(C-H, N-H), 3086(C-H, Ar-H), 2951(C-H, 
CH2), 1663 (C=N), 1491(C=C), 719(C-Cl). 1H-NMR 
(DMSO-d6, δ, ppm): 9.73 (H, s, N-H), 7.89-6.57 (H, m, Ar-
H), 9.11(1H, s, CH, imidazole). ESI-MS (m/z): 330 (M+). 
Anal.calcd. for C21H15ClN2: C, 55.30; H, 4.61; N, 15.71. 
Found: C, 55.41; H, 4.75; N, 15.92.  
Synthesis of 4-(biphenyl-4-yl)-2-(4-bromophenyl)-1H-
imidazole (3vii): Yield: 81%, Mp: 142-145°C, Rf = 0.57. IR 
(KBr, cm-1): 3447(C-H, N-H), 3171 (C-H, Ar-H), 2817 (C-H, 
CH2), 1652 (C=N), 1539 (C=C), 803 (C-Br). 1H-NMR 
(DMSO-d6, δ, ppm): 10.01 (H, s, N-H), 7.91-6.85 (H, m, Ar-
H), 8.71 (1H, s, CH, imidazole). ESI-MS (m/z): 375 (M+). 
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Anal.calcd. for C21H15BrN2: C, 57.21; H, 4.03; N, 7.47. 
Found: C, 56.79; H, 4.07; N, 7.51. 
Synthesis of 4-(biphenyl-4-yl)-2-(4-methoxyphenyl)-1H-
imidazole (3x): Yield: 71%, Mp: 160-163°C, Rf = 0.63. IR 
(KBr, cm-1): 3031(C-H, Ar-H), 2905(C-H, CH2), 1662(C=N), 
1571 (C=C). 1H-NMR (DMSO-d6, δ, ppm): 9.97 (H, s, N-H), 
7.85-6.21 (H, m, Ar-H), 9.03 (1H, s, CH, imidazole), 3.85 (H, 
s, OCH3),. ESI-MS (m/z): 326 (M+). Anal.calcd. for 
C22H18N2O: C, 68.91; H, 5.56; N, 8.51. Found: C, 68.79; H, 
5.51; N, 8.58. 
Synthesis of 3-(4-(biphenyl-4-yl)-1H-imidazol-2-yl) phenol 
(3xi): Yield: 78%, Mp: 140-143°C, Rf = 0.55. IR (KBr, cm-1): 
3421(C-H, N-H), 3307(OH), 3041(C-H, Ar-H), 2867(C-H, 
CH2), 1571(C=N), 1543 (C=C). 1H-NMR (DMSO-d6, δ, 
ppm): 10.11 (H, s, N-H), 7.89-6.68 (H, m, Ar-H), 8.73 (1H, s, 
CH, imidazole), 9.31 (H, s, OH). ESI-MS (m/z): 312 (M+). 
Anal.calcd. for C21H16N2O: C, 55.45; H, 5.19; N, 9.13. 
Found: C, 55.51; H, 5.21; N, 9.21. 
Synthesis of 4-(biphenyl-4-yl)-2-(4-fluorophenyl)-1H-
imidazole (3xii): Yield: 67%, Mp: 171-175 ºC, Rf = 0.45. IR 
(KBr, cm-1): 3127(C-H, Ar-H), 2945(CH2), 1635(C=N), 
1589(C=C), 861 (C-F). 1H-NMR (DMSO-d6, δ, ppm): 11.01 
(H, s, N-H), 8.11-7.23 (H, m, Ar-H), 9.25 (1H, s, CH, 
imidazole). ESI-MS (m/z): 314 (M+). Anal.calcd. for 
C21H15FN2: C, 52.35; H, 4.81; N, 8.91. Found: C, 53.21; H, 
4.93; N, 8.97.  
Antimicrobial Evaluation 
The inhibition of microbial growth under standardized 
condition may be utilized for demonstrating the therapeutic 
efficacy of any subtle change in the antibiotic molecule. 
Which may not be detected by chemical method will be 
revealed by a reduction in the anti-microbial activity and 
hence microbiological assays are very useful for resolving 
doubts regarding possible loss of potency of antibiotics and 
their preparations of the antibiotic having a known activity. 
The in-vitro antibacterial and antifungal activities of the 
synthesized compounds were carried out by microdilution 
susceptibility test using cup-plate technique. Antibacterial 
activity of newly synthesized compounds (3i-xii) was screened 
against bacterial strains viz. Escherichia coli (E. coli, MTCC 
2961), Staphylococcus aureus (S. aureus, MTCC 3160), 
Bacillus subtilis (B. subtilis, MTCC 121), Klebsiella 
pneumoniae (K. pneumoniae, MTCC 3040) and Micrococcus 
luteus (M. luteus, MTCC 7527). The anti-fungal activity was 
screened against fungal strains viz. Candida albicans (C. 
albicans, MTCC 227), Aspergillus niger (A. niger, MTCC 
277) and Aspergillus flavus (A. flavus, MTCC 418). The MIC 
(minimum inhibitory concentration) values were determined 
in compare to standard drug Ciprofloxacin (anti-bacterial) and 
Fluconazole (anti-fungal). The MIC is considered to be the 
lowest drug concentration for which there is no microbial 
growth. 
 
Antibacterial Activity 
Experimental Procedure 
In-vitro antibacterial activity of the synthesized compounds 
was tested by disc diffusion method under standard condition 
using Muller Hinton Agar medium. The test organisms were 
first cultured in Nutrient broth and incubated for 24 hrs at 
37ºC and then freshly prepared bacterial cells were spread 
onto the Muller Hinton agar plates in a laminar flow cabinet. 
The test compounds which were previously dissolved in 
DMSO were then soaked onto sterile discs of Whatman filter 
paper no. 1 (6 mm diameter). The discs were then placed onto 
the surface of the previously prepared inoculated plates and 
incubated. After 24 hrs of incubation at 37ºC, the diameter of 
zone of inhibition was measured for each compound in mm. 
The activity was compared with standard antibiotic 
ciprofloxacin (positive control) and a disc impregnated with 
dimethylsulfoxide (DMSO) was used as a negative control 
[18-19]. All the tests were performed in triplicate and the 
average was taken as final reading. Compounds which have 
shown good zone of inhibition were selected for minimum 
inhibitory concentration (MIC) determination. 
Antifungal activity  
Experimental Procedure  
In-vitro antifungal activity of the synthesized compounds was 
tested by disc diffusion method under standard conditions 
using Potato dextrose agar medium. Sterile discs of Whatman 
filter paper no.1 (6 mm diameter) containing specific amounts 
of an antifungal agent fluconazole (300 mg for the synthesized 
compounds) were placed on the surface of an agar plate 
inoculated with a standardized suspension of the 
microorganisms tested. The plates were incubated at 28±2ºC 
for 72 hrs for evaluating antifungal activity. A paper disc 
impregnated with dimethylsulfoxide (DMSO) was utilized as 
negative control [19-20].The nutrient agar medium was 
prepared and autoclaved at 15 lbs pressure for 20 minutes and 
this media was poured into petri plates and was allowed to 
solidify. On the surface of media microbial suspension was 
spread with the help of sterilized cotton swab. Cups were 
made by boring into agar surface with a previously sterilized 
cork borer and scooping out the punched part of agar. Four 
cavities or cups were made in the medium and different 
concentrations of the test compounds and standard drug 
Fluconazole were poured in these cavities. The plates were 
kept at room temperature for 1 hr and then incubated at 37±0.5 
°C for 24 hrs. The diameter of the zone of inhibition formed 
around the cavities (cups) after 24 hrs incubation was 
measured and percentage inhibition of the compound were 
evaluated. A solvent control was also run to know the activity 
of the blank. 
Determination of MIC  
MIC of the compound was determined by agar streak dilution 
method. A stock solution of the synthesized compounds (100 
µg/mL) in DMSO was prepared and graded quantities of the 
test compounds were incorporated in specified quantity of 
molten sterile agar (Muller Hinton agar). A specified quantity 
of the medium (40-50ºC) containing the compound was 
poured into a Petri dish to give a depth of 3-4 mm and allowed 
to solidify. Suspension of the micro-organism was prepared to 
contain approximately 105 cfu/mL and applied to plates with 
serially diluted compounds in DMSO to be tested and 
incubated at 37ºC. At the end of the incubation period, the 
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MIC values were determined. All determinations were done in 
triplicates and the average was taken as final reading. The 
standard antibiotic, ciprofloxacin (100 µg/mL) used as 
positive control and 100 mL of DMSO used as a negative 
control. The MIC was considered to be the lowest 
concentration of the test substance exhibiting no visible 
growth of bacteria or fungi on the plate [25-26].  
Result and Discussion 
Chemistry 
The title compounds (3i-xii) were synthesized as per synthetic 
scheme outline. In this scheme biphenyl ethanone (1; starting 
material) was treated with selenium dioxide to get 2-
(biphenyl-4-yl)-2-oxoacetaldehyde (2). Compound 2 was 
refluxed with different aromatic aldehydes in presence of 
ammonium acetate and glacial acetic acid, followed by 
treatment with chlorobenzene in THF to get twelve new 
imidazole derivatives (3i-xii).  The structures of newly 
prepared compounds were established on the basis of modern 
analytical techniques (FT-IR, 1H-NMR and mass spectral 
data) and elemental analysis. The final compounds were 
purified by recrystalization with suitable solvent and found 
pure on TLC examination.  
Structural investigations  
The starting material 1-(biphenyl-4-yl) ethanone (biphenyl 
ethanone, 1) was prepared by heating biphenyl with anhydrous 
AlCl3 in the presence of CS2 and acetic anhydride. The usual 
work up of the reaction mixture followed by recrystallized 
from ethanol gave pure compound. The purity of the 
compound was verified with the help of TLC (B: A, 9:1). % 
age of yield was found 83% and melting point noted 151-
152°C. IR spectra are very informative and provided evidence 
for the formation of expected structures. In general, IR spectra 
of acetophenone showed a strong band at 1673 cm-1 for the 
confirmation of C=O. Whereas 1H-NMR further confirmed 
the structure due to the presence of a singlet of CH3 at 2.61 
ppm.  
Compound 2 [2-(biphenyl-4-yl)-2-oxoacetaldehyde] was 
synthesized from 1-(biphenyl-4-yl) ethanone (1) in the 
presence of selenium dioxide and after work out of reaction 
gave a yellow liquid which was found pure on TLC 
examination (TEF 5: 4: 1). The structure of compound was 
confirmed on the basis of spectral studies. In IR spectra 
showed a band at 2851 cm-1 for the confirmation of aldehydic 
C-H stretching was very clear. The 1H-NMR spectra left no 
doubt with a singlet of aldehydic proton at 9.810 ppm. 
Compound 2 [2-(biphenyl-4-yl)-2-oxoacetaldehyde] was 
refluxed with different aromatic aldehyde in the presence of 
ammonium acetate and glacial acetic acid. The usual work up 
of the reaction mixture followed by recrystallized from 
acetone to get the desired products (3i-xii). The compound 
was found pure on TLC examination (TEF 5: 4: 1) and its 
spectral data was found satisfactory for the proposed 
structures. The structure of this compound was confirmed on 
the basis of their IR and 1H-NMR spectral studies. In IR 
spectral studies, the compounds showed intense bands in the 
region 1535-1633 cm-1 of C=N stretching due to the ring 
closure. In addition, the absorption bands at 1351-1367 cm-
1are attributed to the C-N stretching vibrations, which also 
confirm the formation of desired imidazole ring in the 
compounds. Whereas 1H-NMR spectra further confirm the 
structure due to disappearance of the peak of aldehydic proton 
and appearance of a single peak of NH (imidazole ring) at 
11.23 ppm due to ring closure.  
 
 
 
Evaluation of Anti-microbial Screening  The synthetic compounds were prepared retaining the 
functional groups responsible for anti-microbial activity and 
Verma et al. / Indian J. Pharm. Biol. Res., 2017; 5(1):1-9 
 
Research Article  6 
 
tested in-vitro against representatives of Gram positive and 
Gram negative bacteria as well as fungi. It was found that the 
synthesized compounds were more effective against the Gram-
positive bacteria when compared to Gram-negative bacteria. It 
is believed that the strong lipophilic character of the molecule 
play an essential role in producing antimicrobial effect. The 
lipophilicity (hydrophobicity) of a compound is an important 
physical property that influences membrane permeation, 
dissolution rate and bioavailability of compounds which is a 
primary factor in controlling the interaction of drugs with 
biological systems. The lipophilicity of a compound may be 
expressed in terms of log P, which is considered to be very 
important factor for prediction of antimicrobial activity [21-
22]. The octanol/water partition coefficient C logP is a 
measure of hydrophobicity/ lipophilicity. Furthermore, it is a 
crucial factor governing passive membrane partitioning, 
influencing permeability (i.e. increasing logP enhances 
permeability). Drugs with high partition coefficients 
(hydrophobic) are preferentially distributed to lipophilic 
compartments such as lipid bilayers of cells while hydrophilic 
drugs (low partition coefficients) preferentially are found in 
hydrophilic compartments such as blood serum. The values of 
C log P were calculated using Chem Draw Ultra 8.0 software 
integrated with Cambridge Software (Cambridgesoft 
Corporation) obtained results shown in Table 1. Molar 
refractivity (MR), the measure of steric factor, bulkiness of the 
molecule and its polarizability [23-24] was also calculated 
using Chem Draw Ultra 8.0 software integrated with 
Cambridge  Software (Cambridgesoft Corporation) to explain 
the activity behavior of the synthesized compounds and 
obtained results showed  in Table 1. Molar refractivity is the 
molar volume corrected by the refractive index. It has been 
inferred after the correlation of the antimicrobial data with the 
values of C logP and molar refractivity; the compounds having 
greater values of C log P and molar refractivity showed better 
antimicrobial activity. The permeability of the membrane of 
the bacteria plays an important role for the determination of 
antibacterial activity.  The antibacterial activity of the 
compounds may be related to cell wall structure of the 
bacteria. This is possible because the cell wall is essential for 
the survival of many bacteria and some antibiotics are able to 
kill bacteria by inhibiting a step in the peptidoglycan 
synthesis. Gram negative bacteria have a relatively thin cell 
wall consisting of a few layers of peptidoglycan surrounded by 
a second lipid membrane containing lipopoly sachharides and 
lipoproteins. In contrast Gram positive bacteria possess a thick 
cell wall containing many layers of peptidoglycan and teichoic 
acids. These differences in cell wall structure can produce 
differences in the antibacterial susceptibility and some 
antibiotics which are effective against Gram-positive bacteria 
are found to be ineffective against Gram negative bacteria [21-
23]. 
Structural activity relationship  
Furthermore the outer membrane of the Gram-negative 
bacteria is less permeable than the cell wall of Gram positives. 
Therefore synthesized compounds may have shown better 
antibacterial activity towards Gram positive bacteria than 
Gram-negatives. On the basis of obtained result the following 
observations could be made that: Compounds (3iv), (3viii) and 
(3x) was the most potent compound of the series suggesting 
that it may be due to the highest value of log P and molar 
refractivity. In general substitution with electron releasing 
group at any position in either of the hydroxyl (3ii), N-
dimethy (3viii) or methoxy (3ix & 3x) series has constant C 
log P value of its analogues. Substitution with OCH3 group at 
the ortho position showed different C log P values in both 
series. In phenoxy series C log P value is decreased as 
compare to its para analogue due to the reason that OCH3 
group being a bulky molecule with oxygen as its part produces 
repulsion as well as steric hindrance. Therefore Compound 
(3x) having p-OCH3 group is more active than (3ix) having 
m-OCH3 group. This indicated that substitution at para 
position enhanced the antibacterial activity.  
  
             Table 1: Compounds code, Substituted (-R1), log P and molar refractivity of title compounds (3i-xii). 
Compd. Subs. (-R) C log P Molar Refractivity 
3i H 3.91 89.81 
3ii 4-OH 5.83 113.70 
3iii 2-Cl 4.45 112.80 
3iv 3-Cl 6.31 114.63 
3v 3-OH 5.95 107.79 
3vi 4-Cl 5.27 113.01 
3vii 4-Br 5.91 109.35 
3viii 4-N(CH3)2 6.03 112.13 
3ix 3-OCH3 5.73 113.17 
3x 4-OCH3 6.73 113.51 
3xi 2-OH 6.21 112.67 
3xii 4-F 5.58 109.63 
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Anti-bacterial activity  
The results of anti-bacterial screening of all the newly 
synthesized compounds are showed in Table 2 and 3. 
Compound 3iv [4-(biphenyl-4-yl)-2-(3-chlorophenyl)-1H-
imidazole] and  compound 3x [4-(biphenyl-4-yl)-2-(4-
methoxyphenyl)-1H-imidazole] showed notable activity 
against E. coli, B. subtilis and K. pneumoniae. Some of them 
showed moderate activity and others rest good activity. 
Compounds (3ii, 3viii & 3ix) were shown moderate activity 
against E. coli, S. aureus, M. luteus and K. pneumonia, 
whereas compounds (3iii, 3vii, 3xi & 3xii) showed mild 
activity against few bacterial strains. Results of the 
antibacterial activity shown in Table 2 as zone of inhibition 
and Table 3 as percentage inhibition against various bacterial 
strains, while maximum activity was observed at 100 μg/mL.   
  
Table 2: Antibacterial activity measure by zone of inhibition of title compounds
 
(3i-xii) 
Compd. E. coli 
(MTCC-1687) 
S. aureus 
(MTCC-2940) 
B. subtilis 
(MTCC- 441) 
M. luteus(MTCC 
7527) 
K.pneumonia (MTCC 3040) 
50 µg/mL ± SDb 100 µg/ 
mL ± SD 
50 µg/ 
mL ± SD 
100 µg/ 
mL ± SD 
50 µg/mL 
± SD 
100 µg/ 
mL ± SD 
50 µg/ 
mL ± SD 
100 µg/ 
mL±SD 
50 µg/ 
mL ± SD 
100 µg/ mL±SD 
3i 8.11 ± 2.35 14.01 ± 
2.01 
nt nt 8.32 ± 
0.58 
9.20 ± 
1.32 
10.31 ± 
1.58 
9.31 ± 
1.1` 
11.30 ± 
0.51 
12.31 ± 1.15 
3ii 14.13 ± 1.71 16.78 ± 
1.21 
15.61 ± 
1.51 
17.21 ± 
2.51 
13.21 ± 
1.31 
14.21 ± 
1.32 
14.47 ± 
1.32 
17.17 ± 
1.44 
15.41 ± 
1.31 
18.51 ± 1.37 
3iii 12.17 ± 3.26 13.58 ± 
1.27 
nt nt 13.51 ± 
1.37 
15.72 ± 
2.32 
nt nt 12.31 ± 
1.31 
17.31 ± 1.13 
3iv 20.31 ± 1.51 23.53 ± 
1.23 
14.18 ± 
1.32 
16.87 ± 
1.17 
19.17 ± 
1.16 
21.97 ± 
0.67 
15.21 ± 
1.23 
16.54 ± 
1.18 
18.13 ± 
1.15 
20.53 ± 2.13 
3v 15.13 ± 1.33 17.37 ± 
1.04 
13.17 ± 
1.12 
14.65 ± 
1.71 
14.64 ± 
1.52 
15.61 ± 
1.12 
13.61 ± 
1.53 
15.67 ± 
0.58 
14.22 ± 
1.36 
14.61 ± 1.13 
3vi 14.17 ± 1.12 16.31 ± 
1.51 
14.61 ± 
1.45 
15.23 ± 
2.53 
16.6 ± 
1.73 
15.21 ± 
1.25 
11.67 ± 
1.53 
18.31 ± 
1.12 
nt nt 
3vii 16.23 ± 2.35 15.31 ± 
1.53 
nt nt 15.47 ± 
1.23 
17.68 ± 
1.51 
17.21 ± 
1.00 
18.21 ± 
1.01 
15.01 ± 
1.17 
17.12 ± 1.11 
3viii 16.15 ± 1.13 17.36 ± 
2.31 
15.61 ± 
1.45 
16.23 ± 
2.51 
14.61 ± 
1.53 
15.31 ± 
1.11 
15.17 ± 
1.39 
17.61 ± 
0.21 
14.37 ± 
1.13 
16.89 ± 0.55 
3ix 14.15 ± 1.11 16.36 ± 
1.33 
15.17 ± 
1.21 
16.33 ± 
1.11 
13.23 ± 
1.13 
14.83 ± 
1.53 
15.93 ± 
1.15 
17.31 ± 
1.27 
14.31 ± 
1.13 
15.17 ± 1.25 
3x 18.15 ± 1.41 21.61 ± 
1.03 
15.11 ± 
0.5 
17.21± 
1.23 
17.01 ± 
1.31 
19.61 ± 
1.41 
15.16 ± 
1.51 
14.61 ± 
2.13 
17.81 ± 
1.32 
20.61 ± 1.16 
3xi nt nt 13.61 ± 
1.05 
15.61 ± 
1.33 
11.51 ± 
1.72 
13.12 ± 
1.51 
9.61 ± 
1.15 
11.67 ± 
2.36 
nt nt 
3xii 11.68 ± 1.15 15.51 ± 
1.67 
11.23 ± 
2.07 
14.61 ± 
1.57 
12.33 ± 
1.32 
14.61 ± 
1.51 
nt nt 15.11 ± 
1.05 
14.58 ± 2.11 
Cipro. 27.51 ± 1.21 29.11 ± 
1.17 
29.31 ± 
1.41 
30.37 ± 
1.71 
28.45 ± 
1.51 
29.81 ± 
1.61 
28.33 ± 
1.53 
30.17 ± 
1.11 
29.41 ± 
1.41 
30.17 ± 
1.35 
               Measure zone of inhibition in millimeter, SD; Standard Deviation, Compd.; Compunds, Cipro; Ciprofloxacin, nt; means not tested compounds. 
Table 3:Antibacterial activity as percentage inhibition of title compounds
 
(3i-xii) 
Compd E. coli 
(MTCC-1687) 
S. aureus 
(MTCC-2940) 
B. subtilis 
(MTCC- 441) 
M. luteus 
( MTCC 7527) 
K. pneumonia 
(MTCC 3040) 
50µg/ mL ± 
SD 
100 µg/ 
mL±SD 
50 µg/ 
mL± SD 
100 µg/ 
mL± SD 
50 µg/ 
mL ± SD 
100 µg/ 
mL± SD 
50 µg/ 
mL± SD 
100 µg/ 
mL± SD 
50 µg/ 
mL± SD 
100 µg/ 
mL±SD 
3i 40.83 ± 2.21 51.31± 
3.41 
nt nt 44.81 ± 
3.26 
65.19 ± 
3.45 
61.41 ± 
2.72 
38.51 ± 
5.71 
43.15 ± 
4.01 
39.61 ± 3.46 
3ii 61.32 ± 4.31 65.52 ± 
5.43 
60.27 ± 
5.46 
54.67 ± 
3.53 
51.23 ± 
1.74 
54.36 ± 
6.21 
57.83 ± 
5.42 
56.41 ± 
6.27 
62.31 ± 
4.27 
59.61 ± 4.41 
3iii 68.27 ± 4.21 64.71 ± 
5.31 
nt nt 59.71 ± 
4.94 
66.11 ± 
1.23 
nt nt 57.29 ± 
3.21 
64.31 ± 3.82 
3iv 67.11 ± 2.91 57.25 ± 
3.62 
48.62 ± 
3.27 
44.81 ± 
2.61 
64.27 ± 
2.51 
50.31 ± 
3.91 
65.81 ± 
3.15 
61.72 ± 
1.63 
58.11 ± 
2.75 
51.26 ± 5.61 
3v 45.13 ± 5.21 40.61 ± 
5.14 
39.01 ± 
1.91 
38.43 ± 
2.21 
41.41 ± 
4.21 
35.77 ± 
2.81 
47.26 ± 
5.20 
55.39 ± 
2.71 
51.05 ± 
4.31 
40.63 ± 5.21 
3vi 55.41 ± 3.41 48.62 ± 
3.75 
40.41 ± 
5.61 
61.18 ± 
4.10 
32.01 ± 
4.62 
37.51 ± 
4.58 
36.21 ± 
5.63 
40.21 ± 
4.41 
nt nt 
3vii 40.10 ± 4.77 48.52 ± 
3.70 
nt nt 45.86 ± 
3.01 
48.29 ± 
6.91 
57.11 ± 
4.94 
53.51 ± 
1.65 
44.63 ± 
4.77 
51.51 ± 3.71 
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3viii 61.78 ± 4.33 57.22 ± 
2.83 
48.52 ± 
2.01 
45.96 ± 
1.47 
53.52 ± 
2.01 
47.96 ± 
1.47 
61.31 ± 
3.82 
57.71 ± 
2.50 
50.62 ± 
4.32 
45.21 ± 2.35 
3ix 59.31 ± 1.21 56.81 ± 
5.26 
53.94 ± 
2.73 
50.61 ± 
3.37 
51.03 ± 
2.53 
56.86 ± 
7.73 
64.66 ± 
4.60 
57.44 ± 
4.44 
58.85 ± 
3.12 
60.84 ± 7.36 
3x 60.31 ± 1.21 58.81 ± 
5.26 
48.48 ± 
2.06 
51.21 ± 
3.66 
65.51 ± 
4.42 
63.67 ± 
2.79 
59.94 ± 
5.62 
55.61 ± 
1.32 
69.39 ± 
3.26 
64.83 ± 4.24 
3xi nt nt 58.10 ± 
5.61 
50.12 ± 
1.61 
68.05 ± 
1.61 
60.76 ± 
7.17 
53.05 ± 
3.55 
51.04 ± 
5.71 
nt nt 
3xii 48.01 ± 6.11 58.32 ± 
6.51 
50.61 ± 
5.78 
47.94 ± 
3.44 
52.47 ± 
2.11 
54.16 ± 
2.90 
nt nt 48.17 ± 
5.13 
58.31 ± 5.61 
Cipro. 100.00 ± 1.41 100.00 
± 1.52 
100.00 
± 1.65 
100.00 
± 2.37 
100.00 ± 
1.15 
100.00 
± 3.45 
100.00 
± 1.63 
100.00 ± 
4.21 
100.00 
± 5.89 
100.00 ± 2.41 
                 Measure zone of inhibition in percentage inhibition, SD; Standard Deviation, Compd.; Compunds, Cipro; Ciprofloxacin, nt; means not tested compounds 
 
Anti-fungal activity 
The results of anti-fungal screening of all the newly 
synthesized compounds are presented in Table 4 and 5. 
Compound 3iv [4-(biphenyl-4-yl)-2-(3-chlorophenyl)-1H-
imidazole] and compound 3x [4-(biphenyl-4-yl)-2-(4-
methoxyphenyl)-1H-imidazole] were shown notable activity 
against E. coli, B. subtilis and K. pneumoniae. Some of them 
showed moderate activity and others rest good activity. 
Compounds (3ii, 3viii & 3ix), showed moderate activity 
against E. coli, S. aureus, M. luteus and K. pneumonia, while 
compounds (3iii, 3vii, 3xi & 3xii) showed mild activity 
against few bacterial strains.  
The compounds of electron releasing imidazole derivatives 
(3ii, 3iv, 3viii, 3ix, 3x & xi) presented comparatively better 
anti-fungal activity than the compounds of electron 
withdrawing imidazole derivatives (3iii, 3vii & 3xii). 
Regarding the overall anti-fungal activity was found to be the 
most potent compound having meta substituted chloro group 
attached to the aromatic ring and methoxy group on para 
position. Some of the synthesized compounds tested were 
endowed with a medium activity against A. flavus. Results of 
the antifungal activity are reported in Table 4 as zone of 
inhibition and Table 5 as percentage inhibition against various 
fungal strains, while maximum activity was observed at 100 
μg/Ml.  
 
Table 4: Antifungal activity as zone of inhibition of title compounds
 
(3i-xii) 
Compd. C. albicans (MTCC-3617) A. niger (MTCC-281) A. flavus (MTCC 418) 
50 µg/mL ± 
SD 
100 µg/mL ± 
SD 
50 µg/mL ± SD 100 µg/mL ± 
SD 
50 µg/mL ± SD 100 µg/mL ± SD 
3i 15.67 ± 1.53 18.31 ± 1.54 15.67 ± 1.52 19.23 ± 1.08 16.54 ± 1.23 19.13 ± 2.01 
3ii 17.12 ± 2.41 19.63 ± 1.21 19.71 ± 1.56 20.19 ± 1.61 19.67 ± 1.53 21.81 ± 1.64 
3iii 11.61 ± 1.52 19.17 ± 2.26 17.67 ± 1.52 16.33 ± 1.01 nt nt 
3iv 16.21 ± 1.63 18.73 ± 1.08 19.50 ± 1.12 22.67 ± 1.57 21.50 ± 1.32 23.61 ± 1.53 
3v nt nt 16.00 ± 1.00 14.31 ± 1.54 15.03 ± 1.42 16.32 ± 1.53 
3vi 20.61 ± 1.04 24.21 ± 1.14 21.67 ± 1.08 21.31 ± 1.31 23.67 ± 2.08 13.33 ± 2.53 
3vii 14.67 ± 1.63 22.04 ± 1.55 13.33 ± 1.53 16.01 ± 1.06 11.33 ± 1.33 18.56 ± 1.21 
3viii 17.31 ± 1.34 19.09 ± 4.65 14.61 ± 1.53 18.83 ± 1.23 21.67 ± 1.51 22.39 ± 1.04 
3ix 16.67 ± 2.51 15.31 ± 2.53 16.60 ± 1.53 15.31 ± 2.08 nt nt 
3x 17.13 ± 1.04 19.31 ± 1.53 16.01 ± 1.07 19.36 ± 1.53 18.21 ± 1.22 20.31 ± 1.53 
3xi 19.63 ± 3.53 22.20 ± 1.21 13.33 ± 2.51 16.43 ± 1.12 11.31 ± 1.54 17.01 ± 1.32 
3xii nt nt 16.61 ± 1.15 15.81 ± 1.04 15.61 ± 1.47 16.81 ± 1.01 
Fluco. 31.23 ± 1.14 31.81 ± 1.72 30.17 ± 1.32 31.23 ± 1.21 28.56 ± 2.51 31.15 ± 2.13 
Zone of inhibition measure in millimeter, SD; Standard Deviation, Fluco; Fluconazole, nt; means not tested compounds.  
   
Table 5: Antifungal activity as percentage inhibition of the synthetic compounds
 
(3i-xii). 
 
Compd. C. albicans (MTCC-3617) A. niger (MTCC-281) A. flavus (MTCC 418) 
50 µg/mL ± SD 100 µg/mL ± 
SD 
50 µg/mL ± SD 100 µg/mL ± SD 50 µg/mL ± 
SD 
100 µg/mL ± 
SD 
3i 55.31 ± 2.48 55.27 ± 2.63 53.42 ± 1.48 56.21 ± 2.91 43.42 ± 2.48 58.21 ± 3.93 
3ii 54.21 ± 1.23 58.37 ± 2.61 63.02 ± 2.02 66.19 ± 3.79 57.01 ± 3.02 60.13 ± 1.61 
3iii 40.12 ± 3.13 41.82 ± 1.62 47.84 ± 1.12 41.11 ± 1.88 nt nt 
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3iv 55.01 ± 2.07 59.04 ± 2.30 61.01 ± 4.59 63.21 ± 1.61 69.01 ± 1.51 72.33 ± 2.62 
3v nt nt 61.30 ± 3.96 40.29 ± 3.31 65.65 ± 2.91 57.29 ± 5.33 
3vi 47.94 ± 1.11 46.16 ± 3.81 50.61 ± 4.18 41.18 ± 4.44 47.61 ± 7.11 45.15 ± 1.41 
3vii 48.41 ± 4.25 50.31 ± 1.68 41.23 ± 2.14 50.71 ± 2.36 51.21 ± 2.12 56.71 ± 2.35 
3viii 57.19 ± 3.14 63.45 ± 2.80 59.67 ± 5.18 62.23± 2.41 60.31 ± 7.18 63.19 ± 2.44 
3ix 53.19 ± 1.17 57.19 ± 1.67 49.22 ± 2.11 52.71 ± 1.31 54.29 ± 4.11 58.71 ± 2.36 
3x 59.23 ± 2.41 61.27 ± 1.63 65.41 ± 1.41 51.29 ± 3.32 61.23 ± 3.17 63.71 ± 1.31 
3xi 67.09 ± 4.01 64.52 ± 4.30 60.13± 5.59 56.12 ± 1.69 nt nt 
3xii nt nt 45.22 ± 2.11 48.71 ± 1.31 42.29 ± 4.11 51.71 ± 2.36 
Fluco. 100.00 ± 2.35 100.00 ± 2.12 100.00 ± 2.34 100.00 ± 3.43 100.00 ± 2.34 100.00 ± 3.43 
                  Zone of inhibition represented in percentage inhibition, SD; Standard deviation, Fluco; Fluconazole, nt; means not tested compounds. 
Conclusion 
 
A number of compounds 3i-xii [4-(biphenyl-4-yl)-2-
(substituted phenyl)-1H-imidazole] have been successfully 
synthesized. The pharmacological study was performed to 
evaluate the effects of substituent on the antibacterial and 
antifungal activities. The biological activity result revealed 
that all the newly synthetic compounds 3i-xii [4-(biphenyl-4-
yl)-2-(substituted phenyl)-1H-imidazole] exhibited better 
antibacterial activity as compared to antifungal activity in 
compare to reference drug. The results of anti-bacterial 
screening further revealed that among all the compounds, the 
compound (3iv) and (3x) were observed significant anti-
bacterial activity against E. coli, B. subtilis and K. 
pneumoniae while compounds (3ii), (3viii) and (3ix) as well 
as compounds (3xi) and (3vii) showed moderate anti-bacterial 
activity in compare to standard drug ciprofloxacin. The results 
of anti-fungal screening showed that the compound (3ii) and 
(3viii) showed good anti-fungal activity against A. niger and 
A. flavus and compound (3xi) showed notable activity against 
C. albicans. The compound (3vii) and (3ix) were shown 
moderate activity against C. albicans and A. niger.  
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